US RAC Practice Exam Questions With
100% Correct Answers
[Q]Which meeting is held with the FDA for the purpose of reaching concurrence on the
key parameters of the investigational plan for a Class III device?
[A] Agreement meeting
[B] Determination meeting
[C] Presubmission meeting
[D] PMA Day-100 meeting - Answer-[A] Agreement meeting
/.[Q]Which meeting held with the FDA is necessary for an otherwise stalled drug product
development program to proceed?
[A] Type A
[B] Type B
[C] Type C
[D] Type D - Answer-[A] Type A
/.[Q]Which type of meeting is held with the FDA for a Special Protocol Assessment?
[A] Type A
[B] Type B
[C] Type C
[D] Type D - Answer-[A] Type A
/.[Q]Within how many days after FDA's receipt of a written request for a meeting should
the following meetings occur: Type A, Type B, Type C
[A] 15, 30, 45
[B] 30, 45, 60
[C] 30, 60, 90
[D] 30, 60, 75 - Answer-[D] 30, 60, 75
/.[Q]How often does a drug product listing need to occur?
[A] Annually
[B] Every June and December
[C] Quarterly
[D] Once - Answer-[B] Every June and December
/.[Q]Upon receipt of a complete PMA, how many days does the FDA have to approve or
not approve the PMA?
[A] 90
[B] 120
[C] 150
[D] 180 - Answer-[D] 180
/.[Q]What is the one section that is required in an NDA but not in a BLA?
,[A] CMC
[B] Clinical data
[C] Field copy certification
[D] Microbiology - Answer-[C] Field copy certification
/.[Q]What are the possible outcomes to a PMA?
[A] Approval, unacceptable, refusal
[B] Acceptance, pending, rejected
[C] Approval, Approvable, not approvable, denial
[D] Approval letter, complete response letter, refuse to file letter - Answer-[C] Approval,
Approvable, not approvable, denial
/.[Q]What are the possible outcomes to an NDA?
[A]Approval, unacceptable, refusal
[B]Approval letter, complete response letter, refuse to file letter
[C]Approval, not approvable, denial
[D]Acceptance, pending, rejected - Answer-[B]Approval letter, complete response letter,
refuse to file letter
/.[Q]What is the approval timeline for a priority NDA versus a standard NDA?
[A] 10 months, 12 months
[B] 6 months, 10 months
[C] 6 months, 12 months
[D] 12 months, 18 months - Answer-[B] 6 months, 10 months
/.[Q]A new drug is any drug not generally recognized as safe and effective before ____.
[A] 1964
[B] 1948
[C] 1927
[D] 1938 - Answer-[D] 1938
/.[Q]A 510 (k) is required for ____ Class I devices and ____ Class II devices.
[A] Some, most
[B] All, all
[C] All, most
[D] Most, some - Answer-[A] Some, most
/.[Q]Which 510 (k) do you file where a guidance document exists that provides
reasonable assurance that the device's safety and effectiveness have been
established?
[A] Traditional
[B] Standard
[C] Abbreviated
[D] Special - Answer-[C] Abbreviated
, /.[Q]Which 510 (k) do you file where the device modification does not affect its intended
use?
[A] Traditional
[B] Standard
[C] Abbreviated
[D] Special - Answer-[D] Special
/.[Q]A determination of substantial equivalence to a 510 (k) implies ________ to market
the device, not ________ to market the device.
[A] Approval, clearance
[B] Clearance, approval
[C] Permission, approval
[D] Clearance, notification - Answer-[B] Clearance, approval
/.[Q]If the FDA requests additional information while reviewing a 510 (k) submission,
you have ___ days to respond.
[A] 30
[B] 60
[C] 90
[D] 180 - Answer-[D] 180
/.[Q]Which of the following are exempt from premarket notification?
[A] Custom devices
[B] Special devices
[C] Restricted devices
[D] None of the above - Answer-[A] Custom devices
/.[Q]Form FDA ____, Blood Establishment Registration and Product Listing, is used for
submission of registration and product listing information to the FDA.
[A] 4030
[B] 2830
[C] 3356
[D] 1170 - Answer-[B] 2830
/.[Q]Completion of Form FDA ____ is required for all establishments engaged in the
recovery, processing, storage, labeling, packaging, or distribution of any Human Cells,
Tissues, and Cellular and Tissue-Based Products (HCT/Ps), or the screening or testing
of a cell or tissue donor.
[A] 4030
[B] 2830
[C] 3356
[D] 1170 - Answer-[C] 3356
/.[Q]A PMA has a __ day administrative review period and a __ day filing review period.
[A] 30, 60
[B] 15, 30
